Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 55Recurrence 7Lymphoma 6Neoplasms, Plasma Cell 5Immunoglobulin Light-chain Amyloidosis 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Paraproteinemias 2Neoplasms 2Lymphoma, T-Cell 2Lymphoma, Mantle-Cell 2Leukemia, Myeloid, Acute 2beta-Thalassemia 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Thalassemia 1Sarcoma, Myeloid 1Prostatic Neoplasms 1Plasmablastic Lymphoma 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Multi-centric Castleman's Disease 1Macular dystrophy, corneal type 1 1Lymphoproliferative Disorders 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphadenopathy 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

Cytarabine 3Mitoxantrone 2Cladribine 2venetoclax 1pegylated granulocyte colony-stimulating factor 1Sorafenib 1Razoxane 1Leyk 1Idarubicin 1Gemtuzumab 1Etoposide 1Dexrazoxane 1Daunorubicin 1Bortezomib 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Myeloid × Bortezomib × 90 days × Clear all
NCT01371981 2026-06-02

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 3 Completed
1,645 enrolled 32 charts
Other hematologic neoplasmSarcoma

Leukemia, Myeloid, Acute, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡